There is no cure yet, but now, a newly FDA-approved drug is helping to slow its progression before it’s too late.
Biogen is set for a revenue boost thanks to the approval of Alzheimers drug Leqembi. But other companies will also benefit ...
Alzheimer’s drug Leqembi has full FDA approval THE ASSOCIATED PRESS July 7, 2023 at 07:30 JST Share Tweet list Print This image provided by Eisai in January 2023 shows vials and packaging for ...
WASHINGTON--Government health officials on Monday approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated ...
Vigil Neuroscience (NASDAQ:VIGL) said the FDA is allowing a Phase 1 clinical trial for its Alzheimer’s drug candidate VG-3927 to proceed with a partial clinical hold related to the maximum drug ...
Approved by the FDA earlier this year, the Alzheimer's therapy lecanemab is an antibody that reduces the buildup in the brain of a sticky peptide called amyloid-beta (Aβ), which is thought to be ...
The FDA also gave full approval to a drug called Leqembi, which slowed Alzheimer’s patients’ functional and cognitive decline by 27% over 18 months, according to trial data.
A potential new Alzheimer’s drug represses the harmful inflammatory response of the brain’s immune cells, reducing disease ...
Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.
Sep. 18, 2023 — Is it possible that a single biomarker can detect all types of diseases related to dopamine deficiency in the brain? Yes, that's what a research group is discovering. 'We have ...
We’ll send you a myFT Daily Digest email rounding up the latest Vivek Ramaswamy news every morning. US biotech company Roivant Sciences has moved to distance itself from its founder, Vivek ...
An advisory committee to the U.S. Food and Drug Administration unanimously rejected a drug-and-device combination made by a Boston biotech, which the agency had already rejected twice.
